Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended July 31, 1998.
Business Overview: The Company develops, manufactures, and markets healthcare products and services through three primary segments: CooperVision (contact lenses), CooperSurgical (women's healthcare instruments), and Hospital Group of America (psychiatric services).
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | Three Months Ended July 31, 1998 | Nine Months Ended July 31, 1998 |
|---|---|---|
| Net Operating Revenue | $54,180 | $148,782 |
| Income from Operations | $11,280 | $26,775 |
| Net Income | $10,174 | $24,650 |
| Diluted Earnings Per Share | $0.66 | $1.60 |
| Cash and Cash Equivalents (End of Period) | $10,059 | $10,059 |
| Net Cash Provided by Operating Activities | N/A | $2,510 |
| Total Debt (Current + Long-term) | $79,095 | $79,095 |
Margins (Nine Months Ended July 31, 1998):
- Gross Margin (Products): 63%
- Operating Margin: 18.0%
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenue increased 39% year-over-year for the three months ended July 31, 1998 ($54.2M vs. $38.9M) and 47% for the nine-month period ($148.8M vs. $101.0M). This growth was primarily driven by the December 1997 acquisition of Aspect Vision Care, which accounted for approximately 55-56% of the product sales growth.
- Profitability: Net income rose 42% for the quarter ($10.2M vs. $7.2M) and 55% for the nine-month period ($24.7M vs. $15.9M). Income from operations increased 52% and 51% respectively.
- Debt Levels: Total debt increased significantly from $9.6 million at October 31, 1997, to $79.1 million at July 31, 1998. This increase was due to financing the Aspect acquisition, including $27.2 million in promissory notes to former Aspect shareholders and a $17.4 million loan from Midland Bank.
- Cash Flow: Net cash provided by operating activities decreased slightly to $2.5 million for the nine months ended July 31, 1998, compared to $2.9 million in the prior year, impacted by one-time tax payments and inventory buildups for new product launches. Investing activities consumed $48.4 million, primarily for acquisitions and capital expenditures.
Guidance, Outlook, and Risks
- Management Commentary: Management expects margins at CooperSurgical to improve as new proprietary products command higher prices. CooperVision's sales growth is attributed to the Aspect acquisition and the success of the Preference Toric product line. New products introduced in May 1998 (FemExam TestCard, Cerveillance Scope, Infrared Coagulator) are expected to generate significant incremental revenue over the next 3-5 years.
- Stock Buyback: On September 3, 1998, the Board authorized the repurchase of up to 1 million shares of common stock.
- Liquidity: The Company has $9.6 million available under its $50 million KeyBank revolving credit facility. Management believes cash flow from operations will fund ongoing operations, though additional financing may be required for plant expansions or further acquisitions.
- Risks and Contingencies:
- Litigation: A jury awarded GT Laboratories $1.7 million in damages regarding a breach of contract claim. The Company intends to appeal. A settlement with Russo Securities was reached for $400,000, and a settlement with BEI Medical Systems resulted in a $500,000 payment to the Company.
- Environmental: Groundwater contamination (TCA) was identified at one site. The Company has accrued $510,000 for remediation and is negotiating with the New York State DEC.
- Year 2000 Compliance: The Company is implementing a compliance program expected to be substantially completed by mid-1999. Costs to date are not material, but there is a risk of unanticipated costs or operational disruptions.
- Foreign Exchange: A portion of debt is denominated in Pounds Sterling, exposing the Company to exchange rate fluctuations, though forward contracts are used to hedge most of this risk.
Investor Verification Checklist
- Verify the final allocation of the $48.3 million excess purchase price recorded for the Aspect acquisition.
- Monitor the outcome of the GT Laboratories appeal regarding the $1.7 million jury verdict.
- Track the integration of Aspect Vision Care and the realization of projected revenue from new CooperSurgical products (FemExam, Cerveillance Scope).
- Review the Company's ability to service its increased debt load ($79.1M total) given the current interest rate environment and foreign exchange exposure.
- Assess the progress and costs associated with the Year 2000 compliance program.